Sofia Molina1, Gabriela Martinez-Zayas1, Paula V Sainz2, Cheuk H Leung3, Liang Li3, Horiana B Grosu1, Roberto Adachi1, David E Ost4. 1. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; School of Medicine and Health Sciences, Tecnologico de Monterrey, Monterrey, Mexico. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: dost@mdanderson.org.
Abstract
BACKGROUND: Evidence-based guidelines recommend management strategies for malignant pleural effusions (MPEs) based on life expectancy. Existent risk-prediction rules do not provide precise individualized survival estimates. RESEARCH QUESTION: Can a newly developed continuous risk-prediction survival model for patients with MPE and known metastatic disease provide precise survival estimates? STUDY DESIGN AND METHODS: Single-center retrospective cohort study of patients with proven malignancy, pleural effusion, and known metastatic disease undergoing thoracentesis from 2014 through 2017. The outcome was time from thoracentesis to death. Risk factors were identified using Cox proportional hazards models. Effect-measure modification (EMM) was tested using the Mantel-Cox test and was addressed by using disease-specific models (DSMs) or interaction terms. Three DSMs and a combined model using interactions were generated. Discrimination was evaluated using Harrell's C-statistic. Calibration was assessed by observed-minus-predicted probability graphs at specific time points. Models were validated using patients treated from 2010 through 2013. Using LENT (pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group performance score, neutrophil-to-lymphocyte ratio and tumor type) variables, we generated both discrete (LENT-D) and continuous (LENT-C) models, assessing discrete vs continuous predictors' performances. RESULTS: The development and validation cohort included 562 and 727 patients, respectively. The Mantel-Cox test demonstrated interactions between cancer type and neutrophil to lymphocyte ratio (P < .0001), pleural fluid lactate dehydrogenase (P = .029), and bilateral effusion (P = .002). DSMs for lung, breast, and hematologic malignancies showed C-statistics of 0.72, 0.72, and 0.62, respectively; the combined model's C-statistics was 0.67. LENT-D (C-statistic, 0.60) and LENT-C (C-statistic, 0.65) models underperformed. INTERPRETATION: EMM is present between cancer type and other predictors; thus, DSMs outperformed the models that failed to account for this. Discrete risk-prediction models lacked enough precision to be useful for individual-level predictions.
BACKGROUND: Evidence-based guidelines recommend management strategies for malignant pleural effusions (MPEs) based on life expectancy. Existent risk-prediction rules do not provide precise individualized survival estimates. RESEARCH QUESTION: Can a newly developed continuous risk-prediction survival model for patients with MPE and known metastatic disease provide precise survival estimates? STUDY DESIGN AND METHODS: Single-center retrospective cohort study of patients with proven malignancy, pleural effusion, and known metastatic disease undergoing thoracentesis from 2014 through 2017. The outcome was time from thoracentesis to death. Risk factors were identified using Cox proportional hazards models. Effect-measure modification (EMM) was tested using the Mantel-Cox test and was addressed by using disease-specific models (DSMs) or interaction terms. Three DSMs and a combined model using interactions were generated. Discrimination was evaluated using Harrell's C-statistic. Calibration was assessed by observed-minus-predicted probability graphs at specific time points. Models were validated using patients treated from 2010 through 2013. Using LENT (pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group performance score, neutrophil-to-lymphocyte ratio and tumor type) variables, we generated both discrete (LENT-D) and continuous (LENT-C) models, assessing discrete vs continuous predictors' performances. RESULTS: The development and validation cohort included 562 and 727 patients, respectively. The Mantel-Cox test demonstrated interactions between cancer type and neutrophil to lymphocyte ratio (P < .0001), pleural fluid lactate dehydrogenase (P = .029), and bilateral effusion (P = .002). DSMs for lung, breast, and hematologic malignancies showed C-statistics of 0.72, 0.72, and 0.62, respectively; the combined model's C-statistics was 0.67. LENT-D (C-statistic, 0.60) and LENT-C (C-statistic, 0.65) models underperformed. INTERPRETATION: EMM is present between cancer type and other predictors; thus, DSMs outperformed the models that failed to account for this. Discrete risk-prediction models lacked enough precision to be useful for individual-level predictions.
Authors: Anuradha Vasista; Martin Stockler; Andrew Martin; Nick Pavlakis; Katrin Sjoquist; David Goldstein; Sanjeev Gill; Vikram Jain; Geoffrey Liu; George Kannourakis; Yeul Hong Kim; Louise Nott; Stephanie Snow; Matthew Burge; Dean Harris; Derek Jonker; Yu Jo Chua; Richard Epstein; Antony Bonaventura; Belinda Kiely Journal: Oncologist Date: 2019-04-01
Authors: Thomas J Kipps; Freda K Stevenson; Catherine J Wu; Carlo M Croce; Graham Packham; William G Wierda; Susan O'Brien; John Gribben; Kanti Rai Journal: Nat Rev Dis Primers Date: 2017-01-19 Impact factor: 52.329
Authors: Ioannis Psallidas; Nikolaos I Kanellakis; Stephen Gerry; Marie Laëtitia Thézénas; Philip D Charles; Anastasia Samsonova; Herbert B Schiller; Roman Fischer; Rachelle Asciak; Robert J Hallifax; Rachel Mercer; Melissa Dobson; Tao Dong; Ian D Pavord; Gary S Collins; Benedikt M Kessler; Harvey I Pass; Nick Maskell; Georgios T Stathopoulos; Najib M Rahman Journal: Lancet Oncol Date: 2018-06-13 Impact factor: 41.316
Authors: Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir Journal: J Natl Cancer Inst Date: 2014-05-29 Impact factor: 13.506
Authors: Wilfried E E Eberhardt; Alan Mitchell; John Crowley; Haruhiko Kondo; Young Tae Kim; Andrew Turrisi; Peter Goldstraw; Ramon Rami-Porta Journal: J Thorac Oncol Date: 2015-11 Impact factor: 15.609
Authors: Najib M Rahman; Justin Pepperell; Sunita Rehal; Tarek Saba; Augustine Tang; Nabeel Ali; Alex West; Gihan Hettiarachchi; Dipak Mukherjee; Johnson Samuel; Andrew Bentley; Lee Dowson; Jonathan Miles; C Frank Ryan; Ken Y Yoneda; Anoop Chauhan; John P Corcoran; Ioannis Psallidas; John M Wrightson; Rob Hallifax; Helen E Davies; Y C Gary Lee; Melissa Dobson; Emma L Hedley; Douglas Seaton; Nicky Russell; Margaret Chapman; Bethan M McFadyen; Rachel A Shaw; Robert J O Davies; Nick A Maskell; Andrew J Nunn; Robert F Miller Journal: JAMA Date: 2015 Dec 22-29 Impact factor: 56.272